5 funding opportunities are listed in this category
Request for Proposals: Novel Approaches to Drug Discovery for Alzheimer’s Disease
ADDF funds drug discovery research programs from domestic and international investigators in academia and biotechnology companies. In addition, ADDF initiates, sponsors, and co-sponsors conferences to stimulate new ideas and approaches in areas of interest to the Foundation, bringing together physicians, scientists, and policy makers worldwide.
As a biomedical venture philanthropy, ADDF seeks to fill the critical translational funding gap between basic research and later stage drug development. We fund high risk, early stage drug discovery and development projects and catalyze scientists to enter the drug discovery field. We have adapted the operating model and principles of venture capital investing to our philanthropic mission in biomedical research. We help to create new biotechnology companies, and to fund early stage biotechnology companies, with programs dedicated to Alzheimer’s disease drug discovery. We seek a return on investment for all of our grants based on the achievement of scientific milestones. When these milestones are met, funds return to the Foundation to increase our ability to support more research.
ADDF FUNDING PROGRAMS • ADDF Academic Drug Discovery and Development Program seeks to create and support innovative translational programs for Alzheimer’s disease, related dementias and cognitive aging in academic medical centers and universities. Biomarker development studies and innovative proof of concept pilot clinical trials of new approaches to treatment, prevention and early detection are also supported.
• ADDF Biotechnology Development Program supports qualified scientific projects in existing, private, early-stage biotechnology companies. ADDF will provide support for qualified projects in more advanced companies if a clear need for non-profit funding to support the project can be demonstrated and justified.
• ADDF Biotechnology Founders Technology Transfer Program supports academic programs that are eligible for technology transfer and the start-up of new biotechnology companies. Up to 35% of funds from these awards may be employed for expenses related to company formation, such as administrative, legal, patent and third-party vendor costs. RESEARCH FUNDING PRIORITIES • Treatment of Alzheimer’s disease and cognitive aging: ADDF supports drug discovery and drug development efforts towards novel treatments for Alzheimer’s disease and related dementias, and cognitive decline associated with aging. These may include disease modifying agents for preventing or delaying progression as well as cognitive enhancers. ADDF provides funding for target validation and proof-of-concept studies, high throughput screening of chemical libraries, lead discovery and optimization, rational medicinal chemistry, and pre-clinical drug development. ADDF also supports small proof-of principle clinical research studies. • Early detection and prevention: ADDF supports the development of biomarkers, such as advanced brain imaging technologies, CSF and blood tests for the early detection of mild cognitive impairment, Alzheimer’s disease and related dementias. ADDF also supports clinical research projects to improve early detection of cognitive impairment through population-based approaches that can impact large numbers of individuals at risk. GENERAL SUBMISSION GUIDELINES Grant applications are usually solicited by private invitation. Unsolicited proposals are also accepted, but inquiries with ADDF staff are encouraged to determine the Foundation’s interest prior to application. ADDF provides support for 1 year of research with potential for future follow-on funding. We seek successful long-term partnerships with investigators and research organizations.
APPLICATION PROCEDURE Full application guidelines and further information can be found on our website (www.alzdiscovery.org). All applicants are required to complete an electronic "Letter of Intent" (LOI) available on our website. After review of the LOI, we may invite a full application via email with a link to the electronic application form. ADDF will attempt to make a determination of interest within 90 days of receipt of the application.
ADDF accepts grant applications for the “General Request for Proposals” research award programs throughout the year (2010 deadlines for full proposals are January 7, April 1, July 1, and October 1).
If you would like to contact the Foundation, please call (212) 935-2402, or contact us by regular mail at the following address:Alzheimer’s Drug Discovery Foundation1414 Avenue of the Americas, Suite 1502New York, NY 10019
Medicinal Chemistry and Drug Metabolism/Pharmacokinetics Partners to Support Lead Discovery for Infectious Tropical Diseases
TDR is supporting innovative research on neglected disease through focused and time-limited activities. The Lead Discovery Business line of TDR (LDR) aims to facilitate the discovery of new drug leads for infectious tropical diseases through North- South networks and partnerships between public and private sectors as well as academic institutions. Through the TDRs screening activities, several confirmed hits and lead compounds have become available for further SAR exploration and progression for several TDR target diseases including schistosomiasis, onchocerciasis, filariasis, African sleeping sickness, leishmaniasis, Chagas disease, malaria and tuberculosis.We are now seeking partners with expertise in medicinal chemistry, and DMPK to take on the optimization of available molecules evaluated through the TDR screening network. We strongly encourage applications from developing countries as we hope that work on these molecules will contribute to development of innovation in developing countries and contribute to the implementation of emerging regional innovation networks exemplified by the African Network for Drugs and Diagnostics Innovation (ANDI) and ongoing discussions for Asian and South American Networks.Project descriptionAcademic and research institutions, biotech and pharmaceutical companies possessing processes and capabilities in medicinal chemistry, drug metabolism and/or pharmacokinetics are encouraged to apply. Collaboration objectives are to: * Support development of molecules through different research stage (Hit to Lead and Lead optimization) * Work as part of the TDR drug discovery network and reporting of SAR data (chemical or biological information) to the TDR database * Collaborate with the existing North South screening or DMPK networks of TDR for biological testing of compounds * Participate in the development of project objectives, timelines, as well as implementation of action points identified by the TDR drug discovery committee. * Participate in the identification of downstream partners for further compound progression and development, for example, transfer of project to the regional networks including local public private partnerships. * Support training of fellows from disease endemic countries as an integral part of the project. Candidate SelectionProposals will be evaluated on the basis of the following criteria: experience and track record and experience of Principal Investigator (PI) and institution in synthetic or medicinal chemistry and DMPK, availability of basic infrastructure for synthetic/medicinal chemistry and DMPK, access to primary in vitro screens, and ability to guide post-doctoral chemists in the synthesis of analogues to explore SAR for optimization of anti-parasitic activity of compounds. Applicants are asked to develop a detailed implementation proposal covering technical and capacity building elements, budget and timelines.DeadlineThe deadline for proposals is March 31st 2010. Selected applicants will be contacted after the reviewing process.How to applyPlease contact Ms Socorro Alias with any queries. The TDR Collaborative Research Grant form template should be used for all proposals.On completion please submit electronically to aliass@who.int before the above deadline. Any additional documents may be submitted as appendices to this form (e.g. CVs of PI and research team, institutional letter of support).
TDR, a Special Programme for Research and Training in Tropical Diseases, is a global programme of scientific collaboration that helps coordinate, support and influence global efforts to combat a portfolio of major diseases of the poor and disadvantaged.Established in 1975, TDR is based at and executed by the World Health Organization (WHO), and is sponsored by the United Nations Children's Fund (UNICEF), the United Nations Development Programme (UNDP), the World Bank and WHO.
Special Programme for Research & Training in Tropical Diseases (TDR)World Health OrganizationAvenue Appia 201211 Geneva 27SWITZERLAND
Tetrahedron Young Investigator Awards in the Fields of Organic Synthesis and of Bioorganic and Medicinal Chemistry - 2011: Call for Nominations
For the 2011 Awards, nominees are to be under 45 years of age at 1 July 2011, and nominations should consist of a covering letter, a brief biographical sketch (max 2-pages), and a list of no more than 15 publications. Other than the age reservation above, nominations will be welcomed for all candidates, from all nationalities. The deadline for nominations is May 1, 2010.Each award will have a separate voting committee, with the Editors of Tetrahedron, Tetrahedron Letters, and Tetrahedron: Asymmetry voting on the Organic Synthesis Award, and the Editors of Bioorganic and Medicinal Chemistry, and Bioorganic and Medicinal Chemistry Letters, voting on the Bioorganic and Medicinal Chemistry Award. Members of the voting committees may not be candidates, nor make nominations.For further information on the Tetrahedron Young Investigator Awards, please contact:Diddel FrancissenExecutive Publisher, ElsevierChemistryEmail: d.francissen@elsevier.com The Tetrahedron Young Investigator Awards were created in 2005 by the Executive Board of Editors and the Publisher of Tetrahedron Publications. These two new awards will be presented to two individuals who have exhibited "exceptional creativity and dedication" in the fields of Organic Synthesis and of Bioorganic and Medicinal Chemistry respectively.The winners each receive US $1,000, a certificate, and an invitation to present a plenary lecture during the annual Tetrahedron Symposium. In 2010 the plenary lectures will be presented during the External link 11th Tetrahedron Symposium in Beijing, China, June 22-25, 2010. Furthermore, two Symposium-in-Print will be compiled in their honour. As with the Tetrahedron Prize for Creativity in Organic Chemistry, which these awards complement, the awards are made on an annual basis.
1
